Wegovy maker's board shaken up as directors quit

Last month the firm issued a warning on profits due to increased competition from US rivals, and announced a cost-savings programme as it cut its profit growth forecast for the third time this year. Widespread adoption of Novo Nordisk's Ozempic diabetes treatment, which is often used off-label as a...

Redirecting to full article...